Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'

Ann Oncol. 2022 Feb;33(2):227-228. doi: 10.1016/j.annonc.2021.10.015. Epub 2021 Oct 29.

Authors

N Harbeck¹, P Rastogi², A Shahir³, S Johnston⁴, J O'Shaughnessy⁵

Affiliations

¹ Breast Center, LMU University Hospital, Munich, Germany. Electronic address: Nadia.Harbeck@med.uni-muenchen.de.
² University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, USA.
³ Eli Lilly and Company, Indianapolis, USA.
⁴ Royal Marsden NHS Foundation Trust, London, UK.
⁵ Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA.

PMID: 34756989
DOI: 10.1016/j.annonc.2021.10.015

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Aminopyridines
Benzimidazoles / therapeutic use
Breast Neoplasms* / drug therapy
Female
Humans
Ki-67 Antigen

Substances

Aminopyridines
Benzimidazoles
Ki-67 Antigen
abemaciclib